| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Zhang,Dong-Xuan | Chairman | 3.97% | |
| TAIWAN ADVANCE BIO-PHARMACEUTICAL INC. | Director | 2.87% | |
| Su,Xiu-E | Director | 2.03% | |
| Yang,Mei-Jun | Director | 0.58% | |
| Cai,Ling-Jun | Independent Director | 0.00% | |
| Lin,Jiong-Sen | Independent Director | 0.00% | |
| Xu,Guang-Yang | Independent Director | 0.00% |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating income | 13,569 | 14,701 | 2,542 |
| Operating cost | 1,833 | 7,380 | 1,547 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 11,736 | 7,321 | 995 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 11,736 | 7,321 | 995 |
| Operating expenses | 63,638 | 253,437 | 260,859 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | -51,902 | -246,116 | -259,864 |
| Non-operating income and expenses | 7,424 | 16,435 | 96,147 |
| Net profit (loss) before tax | -44,478 | -229,681 | -163,717 |
| Income tax expense (benefits) | 0 | 24 | 14,645 |
| Net profit (loss) of ongoing business for the current period | -44,478 | -229,705 | -178,362 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | -44,478 | -229,705 | -178,362 |
| Other comprehensive profit (loss), net | 305 | -236 | -654 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | -44,173 | -229,941 | -179,016 |
| Net profit (loss) attributable to owners of parent company | -44,478 | -229,705 | -178,362 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | - | - | - |
| Comprehensive profit (loss) attributable to owners of parent company | -44,173 | -229,941 | -179,016 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | - | - |
| Basic earnings per share (yuan) | 0 | -2 | -1 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | -44,347 | -221,968 | -183,922 |
| Net cash inflows (outflows) from investing activities | 34,373 | 181,997 | 257,925 |
| Net cash inflow (outflow) from financing activities | 16 | 12 | -6,723 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | - | - | - |
| Increase (decrease) in cash and cash equivalents in the current period | -9,958 | -39,959 | 67,280 |
| Beginning balance of cash and cash equivalents | 109,508 | 149,467 | 82,187 |
| Ending balance of cash and cash equivalents | 99,550 | 109,508 | 149,467 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Current asset | 467,382 | 481,202 | 718,333 |
| Non-current asset | 828,208 | 835,278 | 834,481 |
| Total asset | 1,295,590 | 1,316,480 | 1,552,814 |
| Current liability | 287,932 | 264,635 | 270,583 |
| Non-current liability | 5,357 | 5,371 | 5,816 |
| Total liability | 293,289 | 270,006 | 276,399 |
| share capital | 1,082,081 | 1,086,401 | 1,086,401 |
| Equity - secruity token | - | - | - |
| capital reserve | 201,066 | 196,746 | 374,857 |
| retained earning | -273,846 | -229,368 | -178,111 |
| Other equity | -7,000 | -7,305 | -6,732 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | 1,002,301 | 1,046,474 | 1,276,415 |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | - | - |
| Total Equity | 1,002,301 | 1,046,474 | 1,276,415 |
| Share capital awaiting retirement (unit: share) | 432,000 | 0 | 0 |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 9 | 9 | 11 |
